Harmony Biosciences Holdings, Inc. (HRMY)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $2.45B
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Latest financial period: June 30, 2026
Filed with the SEC: August 4, 2026
Estimated earnings date: November 3, 2026
Not currently ranked. Cannot calculate: FCF yield
Profit Not currently ranked
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | 37.8% | 33.9% | 43.9% | 43.3% |
Growth Not currently ranked
Payout Not currently ranked
Safety Not currently ranked
Price Not currently ranked
